PRENSKY ZACHARY 4

Accession 0001415889-25-024448

CIK 0001691082other

View on SEC.gov Company Profile

Filed

Sep 11, 8:00 PM ET

Accepted

Sep 12, 6:25 PM ET

Size

27.9 KB

Accession

0001415889-25-024448

Insider Transaction Report

Form 4

Period: 2025-09-10

LB PHARMACEUTICALS INCLBRX

PRENSKY ZACHARY

Director

Transactions

Disposition to Issuer
Stock Option (Right to Buy)
2025-09-10−3,944→ 0 total
Exercise: $64.15Exp: 2028-11-13→ Common Stock (3,944 underlying)
Award
Stock Option (Right to Buy)
2025-09-10+3,944→ 3,944 total
Exercise: $15.00Exp: 2028-11-13→ Common Stock (3,944 underlying)
Award
Stock Option (Right to Buy)
2025-09-10+1,255→ 1,255 total
Exercise: $15.00Exp: 2030-08-30→ Common Stock (1,255 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2025-09-10−17,929→ 0 total
Exercise: $41.84Exp: 2033-08-24→ Common Stock (17,929 underlying)
Award
Stock Option (Right to Buy)
2025-09-10+17,929→ 17,929 total
Exercise: $15.00Exp: 2033-08-24→ Common Stock (17,929 underlying)
Award
Stock Option (Right to Buy)
2025-09-10+53,787→ 53,787 total
Exercise: $15.00Exp: 2034-06-26→ Common Stock (53,787 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2025-09-10−896→ 0 total
Exercise: $69.72Exp: 2029-12-22→ Common Stock (896 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2025-09-10−1,255→ 0 total
Exercise: $69.72Exp: 2030-08-30→ Common Stock (1,255 underlying)
Award
Stock Option (Right to Buy)
2025-09-10+896→ 896 total
Exercise: $15.00Exp: 2029-12-22→ Common Stock (896 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2025-09-10−53,787→ 0 total
Exercise: $41.84Exp: 2034-06-26→ Common Stock (53,787 underlying)
Award
Stock Option (Right to Buy)
2025-09-10+22,449→ 22,449 total
Exercise: $15.00Exp: 2035-09-09→ Common Stock (22,449 underlying)

Footnotes (5)

[F1]Immediately exercisable.
[F2]The transactions reported herein reflect a one-time stock option repricing, effective on September 10, 2025, which reduced the per share exercise price of each repriced option to $15, representing the initial public offering price of the Issuer's common stock (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting, remain in full force and effect.
[F3]One fourth (1/4) of the shares subject to the option award vested on August 25, 2024 and the remaining shares subject to the option vested or shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.
[F4]One fourth (1/4) of the shares subject to the option award vested on June 28, 2025 and the remaining shares subject to the option vested or shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.
[F5]The option award shall vest in three (3) equal annual installments on September 10, 2026, September 10, 2027 and September 10, 2028, subject to the Reporting Person's continuous service through such vesting date.

Documents

1 file

4
form4-09122025_060911.xmlPrimary

Issuer

LB PHARMACEUTICALS INC

CIK 0001691082

→

Entity typeother

Related Parties

filerCIK 0001167585

Filing Metadata

Form type: 4
Filed: Sep 11, 8:00 PM ET
Accepted: Sep 12, 6:25 PM ET
Size: 27.9 KB

View on SEC.gov